Free tool
FAERS Monitor: Cimduo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022141 or its brand name (Cimduo, Lamivudine, Tenofovir Disoproxil Fumarate). Reports on generic versions are filed under their own applications.
Reports
42
Serious
37
88% of reports
Hospitalization
5
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- foetal exposure during pregnancy12
- maternal exposure during pregnancy10
- abortion spontaneous6
- anhedonia5
- anxiety5
- emotional distress5
- pain5
- premature baby4
- depression3
- exposure during pregnancy3
- osteoporosis3
- premature delivery3
- subchorionic haematoma3
- abortion induced2
- acute kidney injury2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 16 |
| 2020 | 12 |
| 2021 | 2 |
| 2022 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,117 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| subchorionic haematomaSignal | 3 | 8692.9 | 2891.9 | 17,797 |
| abortion induced | 2 | 106.4 | 27.5 | 117 |
| anhedoniaSignal | 5 | 95.3 | 41.9 | 377 |
| premature deliverySignal | 3 | 94.4 | 31.7 | 192 |
| abortion spontaneousSignal | 6 | 75.0 | 35.8 | 368 |
| foetal exposure during pregnancySignal | 12 | 73.9 | 45.8 | 795 |
| premature babySignal | 4 | 66.6 | 26.2 | 197 |
| maternal exposure during pregnancySignal | 10 | 56.2 | 32.7 | 490 |
| osteoporosisSignal | 3 | 36.5 | 12.3 | 71 |
| exposure during pregnancySignal | 3 | 24.2 | 8.1 | 46 |
| emotional distressSignal | 5 | 20.7 | 9.1 | 75 |
| anxietySignal | 5 | 8.8 | 3.9 | 28 |
| depressionSignal | 3 | 6.6 | 2.2 | 9 |
| acute kidney injury | 2 | 6.5 | 1.7 | 5 |
| painSignal | 5 | 4.1 | 1.8 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.